Survodutide: difference between revisions
Diff·revision 15 → 16·09:57, 2 Aug 2025
Difference between revision 15 and revision 16 of Survodutide. 6 lines changed; the page grew by 774 bytes.
| Revision 15 — 12:55, 7 Jul 2025 INN_Ingrid (talk) give the INN alongside the trade name at first mention 4,528 bytes +18 | Revision 16 — 09:57, 2 Aug 2025 IcodecIndra (talk) add the receptor targets to the lead sentence 5,302 bytes +774 | ||
|---|---|---|---|
| 29 | Gastrointestinal adverse events dominated and were dose-related. A heart-rate increase attributable to the glucagon component was reported, as it was for retatrutide, and rises in fasting glucose were observed early in escalation in some participants — the anticipated consequence of glucagon agonism outpacing GLP-1 agonism at low total dose.{{r|zimmermann2022}} | 29 | Gastrointestinal adverse events dominated and were dose-related. A heart-rate increase attributable to the glucagon component was reported, as it was for retatrutide, and rises in fasting glucose were observed early in escalation in some participants — the anticipated consequence of glucagon agonism outpacing GLP-1 agonism at low total dose.{{r|zimmermann2022}} |
| 30 | 30 | ||
| + | 31 | == Status and material sold under the name == | |
| + | 32 | Survodutide has not been approved in any jurisdiction. Phase 3 programmes in obesity and in steatohepatitis are ongoing, and this article will require revision as they report. | |
| + | 33 | ||
| + | 34 | Material offered as survodutide by research-chemical suppliers is an unapproved investigational compound. As with [[Retatrutide|retatrutide]], there is no marketed reference product and therefore no generally available [[Reference standard|reference standard]] against which identity could be confirmed by comparison, so a purity figure on a certificate rests on an unverified identity assignment.{{r|usp1503}} | |
| + | 35 | ||
| 31 | == References == | 36 | == References == |
| 32 | {{reflist}} | 37 | {{reflist}} |
| 33 | <ref name="zimmermann2022">Zimmermann T, Thomas L, Baader-Pagler T, et al. "BI 456906: discovery and preclinical pharmacology of a novel GCGR/GLP-1R dual agonist with robust anti-obesity efficacy." ''Molecular Metabolism'' 66:101633 (2022). DOI:10.1016/j.molmet.2022.101633. PMID 36372428.</ref> | 38 | <ref name="zimmermann2022">Zimmermann T, Thomas L, Baader-Pagler T, et al. "BI 456906: discovery and preclinical pharmacology of a novel GCGR/GLP-1R dual agonist with robust anti-obesity efficacy." ''Molecular Metabolism'' 66:101633 (2022). DOI:10.1016/j.molmet.2022.101633. PMID 36372428.</ref> |
| 34 | <ref name="blueher2024">Blüher M, Rosenstock J, Hoefler J, Manuel R, Hennige AM. "Dose-response effects on HbA1c and bodyweight reduction of survodutide, a dual glucagon/GLP-1 receptor agonist." ''Diabetologia'' 67(3):470–482 (2024). PMID 38095713.</ref> | 39 | <ref name="blueher2024">Blüher M, Rosenstock J, Hoefler J, Manuel R, Hennige AM. "Dose-response effects on HbA1c and bodyweight reduction of survodutide, a dual glucagon/GLP-1 receptor agonist." ''Diabetologia'' 67(3):470–482 (2024). PMID 38095713.</ref> |
| + | 40 | <ref name="usp1503">United States Pharmacopeia, General Chapter <1503>, ''Quality Attributes of Synthetic Peptide Drug Substances''.</ref> | |
| 35 | <ref name="campbell2013">Campbell JE, Drucker DJ. "Pharmacology, physiology, and mechanisms of incretin hormone action." ''Cell Metabolism'' 17(6):819–837 (2013). PMID 23684623.</ref> | 41 | <ref name="campbell2013">Campbell JE, Drucker DJ. "Pharmacology, physiology, and mechanisms of incretin hormone action." ''Cell Metabolism'' 17(6):819–837 (2013). PMID 23684623.</ref> |
| 36 | 42 |